Ninjin'yoeito reduces fatigue-like conditions by alleviating inflammation of the brain and skeletal muscles in aging mice.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Muscle, Skeletal*/drug effects ; Muscle, Skeletal*/metabolism ; Aging*/drug effects ; Fatigue*/drug therapy ; Brain*/drug effects ; Brain*/metabolism ; Brain*/pathology ; Drugs, Chinese Herbal*/pharmacology ; Drugs, Chinese Herbal*/therapeutic use ; Inflammation*/drug therapy ; Inflammation*/pathology; Animals ; Mice ; Male ; Interleukin-1beta/metabolism

Fatigue can lead to several health issues and is particularly prevalent among elderly individuals with chronic inflammatory conditions. Ninjin'yoeito, a traditional Japanese herbal medicine, is used to address fatigue and malaise, anorexia, and anemia. This study aimed to examine whether relieving inflammation in the brain and skeletal muscle of senescence-accelerated mice prone 8 (SAMP8) could reduce fatigue-like conditions associated with aging. First, SAMP8 mice were divided into two groups, with and without ninjin'yoeito treatment. The ninjin'yoeito-treated group received a diet containing 3% ninjin'yoeito for a period of 4 months starting at 3 months of age. At 7 months of age, all mice underwent motor function, treadmill fatigue, and behavioral tests. They were then euthanized and the skeletal muscle weight, muscle cross-sectional area, and concentration of interleukin (IL)-1β and IL-1 receptor antagonist (IL-1RA) in both the brain and skeletal muscle were measured. The results showed that the ninjin'yoeito-treated group had higher motor function and spontaneous locomotor activity than the untreated group did and ran for significantly longer in the treadmill fatigue test. Moreover, larger muscle cross-sectional area, lower IL-1β concentrations, and higher IL-1RA concentrations were observed in both the brain and skeletal muscle tissues of the ninjin'yoeito-treated group than in the untreated group. The results suggest that ninjin'yoeito improves age-related inflammatory conditions in both the central and peripheral tissues and reduces fatigue.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: KM and YM are company employees of the funding partner, Tsumura & Co. However, they have only funded the study and have no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
(Copyright: © 2024 Otsuka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Exp Neurol. 2021 Mar;337:113590. (PMID: 33388314)
Curr Med Chem. 2019;26(10):1833-1848. (PMID: 28413958)
J Altern Complement Med. 2015 May;21(5):281-7. (PMID: 25918996)
Nutrients. 2019 Sep 30;11(10):. (PMID: 31574939)
Rheumatol Int. 2005 Aug;25(6):481-4. (PMID: 15071755)
J Vis Exp. 2016 May 31;(111):. (PMID: 27286034)
Neuroscience. 2017 Sep 1;358:115-123. (PMID: 28684277)
J Ethnopharmacol. 2021 Oct 28;279:114332. (PMID: 34129897)
J Ethnopharmacol. 2021 Jan 30;265:113317. (PMID: 32861821)
Am J Physiol Regul Integr Comp Physiol. 2006 Nov;291(5):R1344-8. (PMID: 16778069)
Front Nutr. 2018 Aug 21;5:72. (PMID: 30186837)
Stem Cell Res Ther. 2022 Jun 3;13(1):226. (PMID: 35659361)
Nutrients. 2021 Sep 06;13(9):. (PMID: 34578998)
J Neuroinflammation. 2017 Dec 20;14(1):256. (PMID: 29262843)
Biomolecules. 2020 Jan 01;10(1):. (PMID: 31906307)
PLoS One. 2014 Mar 12;9(3):e90950. (PMID: 24621600)
J Neuroinflammation. 2017 Jan 21;14(1):16. (PMID: 28109186)
J Ethnopharmacol. 2022 Feb 10;284:114767. (PMID: 34710555)
Brain Behav Immun. 2009 Jul;23(5):573-9. (PMID: 19258032)
Brain Behav Immun. 2012 Nov;26(8):1202-10. (PMID: 22732129)
Nutrients. 2016 Apr 07;8(4):205. (PMID: 27070637)
Med Sci Sports Exerc. 2009 Oct;41(10):1869-75. (PMID: 19727027)
Front Nutr. 2018 Dec 12;5:126. (PMID: 30619872)
Biomolecules. 2020 Mar 13;10(3):. (PMID: 32183094)
Biosci Biotechnol Biochem. 2021 May 25;85(6):1506-1513. (PMID: 33739383)
Aging (Albany NY). 2020 Feb 16;12(4):3175-3189. (PMID: 32065782)
Arthritis Res Ther. 2023 Sep 14;25(1):168. (PMID: 37710278)
Int J Mol Sci. 2021 Oct 27;22(21):. (PMID: 34769017)
Biomed Pharmacother. 2019 Mar;111:1376-1382. (PMID: 30841452)
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):538-554. (PMID: 33951340)
J Food Biochem. 2021 Nov;45(11):e13968. (PMID: 34651301)
Biol Pharm Bull. 2020;43(1):110-115. (PMID: 31902915)
Eur J Neurosci. 2014 Oct;40(8):3253-63. (PMID: 25040499)
Front Endocrinol (Lausanne). 2022 Aug 26;13:915937. (PMID: 36093084)
Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S57-64. (PMID: 14563522)
Int J Tryptophan Res. 2020 Jun 29;13:1178646920936279. (PMID: 32647476)
Front Immunol. 2018 Apr 09;9:586. (PMID: 29686666)
J Mol Neurosci. 2021 Oct;71(10):1975-1986. (PMID: 33586033)
Front Nutr. 2020 Feb 27;7:5. (PMID: 32175325)
Int J Mol Sci. 2022 Sep 23;23(19):. (PMID: 36232484)
Front Nutr. 2018 Oct 08;5:93. (PMID: 30349821)
Biomed Pharmacother. 2018 Oct;106:92-97. (PMID: 29957471)
Med Sci Sports Exerc. 2016 Oct;48(10):1917-24. (PMID: 27187099)
J Alzheimers Dis Rep. 2017 Dec 9;1(1):229-235. (PMID: 30480240)
Ageing Res Rev. 2021 May;67:101261. (PMID: 33548508)
Meat Sci. 2015 Nov;109:96-100. (PMID: 26021783)
Front Aging Neurosci. 2015 Jul 16;7:129. (PMID: 26236231)
J Ethnopharmacol. 2023 Feb 10;302(Pt B):115927. (PMID: 36402237)
Neuropharmacology. 2016 Nov;110(Pt A):503-518. (PMID: 27543415)

0 (ninjin'yoeito)

Date Created: 20240520 Date Completed: 20240520 Latest Revision: 20240522

20250114

PMC11104581

10.1371/journal.pone.0303833

38768175